Erytech Pharma S.A.

4.5000.00Vol 10.18K1Y Perf -43.68%
Jul 27th, 2021 11:30 DELAYED
BID4.33 ASK4.66
Open4.49 Previous Close4.50
Pre-Market- After-Market-
 - -%  - -
Target Price
22.50 
Analyst Rating
Strong Buy 1.00
Potential %
400.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap118.85M 
Earnings Rating
Neutral
Price Range Ratio 52W %
3.08 
Earnings Date
4th May 2021

Today's Price Range

4.394.50

52W Range

4.2013.95

5 Year PE Ratio Range

-10.40-3.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.45%
1 Month
-3.64%
3 Months
-38.36%
6 Months
-61.07%
1 Year
-43.68%
3 Years
-56.90%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ERYP4.500.00000.00
AAPL146.17-2.8200-1.89
GOOG2 713.87-79.0200-2.83
MSFT283.48-5.5700-1.93
XOM57.60-0.8800-1.50
WFC45.100.09000.20
JNJ172.330.46000.27
FB365.27-7.1900-1.93
GE13.120.20001.55
JPM151.790.14000.09
Earnings HistoryEstimateReportedSurprise %
Q04 2019-0.86-1.21-40.70
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.9077.10Positive
3/2021 QR-0.7021.35Positive
12/2021 FY-3.106.06Positive
12/2022 FY-2.539.32Positive
Next Report Date-
Estimated EPS Next Report-0.89
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume10.18K
Shares Outstanding26.41M
Trades Count79
Dollar Volume68.70K
Avg. Volume18.28K
Avg. Weekly Volume37.02K
Avg. Monthly Volume18.08K
Avg. Quarterly Volume13.72K

Erytech Pharma S.A. (NASDAQ: ERYP) stock closed at 4.5 per share at the end of the most recent trading day (a -5.26% change compared to the prior day closing price) with a volume of 15.82K shares and market capitalization of 118.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 217 people. Erytech Pharma S.A. CEO is Gil Beyen.

The one-year performance of Erytech Pharma S.A. stock is -43.68%, while year-to-date (YTD) performance is -51.25%. ERYP stock has a five-year performance of %. Its 52-week range is between 4.2 and 13.95, which gives ERYP stock a 52-week price range ratio of 3.08%

Erytech Pharma S.A. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 3.67, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -71.91%, a ROC of -69.55% and a ROE of -99.63%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Erytech Pharma S.A., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Erytech Pharma S.A.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Erytech Pharma S.A. is Strong Buy (1), with a target price of $22.5, which is +400.00% compared to the current price. The earnings rating for Erytech Pharma S.A. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Erytech Pharma S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Erytech Pharma S.A. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.76, ATR14 : 0.38, CCI20 : -47.92, Chaikin Money Flow : -0.30, MACD : -0.18, Money Flow Index : 54.17, ROC : -3.23, RSI : 43.01, STOCH (14,3) : 22.22, STOCH RSI : 0.44, UO : 37.03, Williams %R : -77.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Erytech Pharma S.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Erytech Pharma S.A.

Erytech Pharma SA is a clinical-stage biopharmaceutical company. It is engaged in conducting activities in research and development in the fields of treatment for acute leukemia and other orphan diseases. The approach by the firm consists of acting on the tumor's environment and starving it so that the cancerous cells no longer have access to the growth factors that are necessary to live and proliferate. Most of the activities of the group are located in France. The company ERYCAPS proprietary platform to encapsulate active drug substances inside red blood cells using reversible hypotonic and hypertonic osmotic stress. The company's geographical segments are France and the United States, out of which the United States contributes to the majority of the revenue.

CEO: Gil Beyen

Telephone: +33 478744438

Address: 60 Avenue Rockefeller, Lyon 69008, , FR

Number of employees: 217

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

29%71%

Bearish Bullish

61%39%

Bearish Bullish

58%42%

News

Stocktwits